

Sexuality and Hormones

Ms A P Hawkins

BSc MBBS MRCOG DFSRH

Consultant in Obstetrics and Gynaecology

Member of the Institute of Psychosexual Medicine

BMS Menopause Specialist, NAPS Trustee

08/02/2025

Declaration of interests

British Menopause Society: Accredited BMS Menopause Specialist. Previous Member of Medical Advisory Council Executive.

Trustee and medical advisor to the National Association of Premenstrual Syndrome

Member of the Institute of Psychosexual Medicine, Previous Exec and Trustee

Previous Exec Treasurer and Trustee of the British Society of Psychological Obstetrics, Gynaecology and Andrology

Member of the British Fertility Society



Salisbury NHS

NHS Foundation Trust

Sponsorship


2001-4 Travel grants -Galen and Ferring

- 2002 Clinical trial Servier
- 2019 Consultant for Shionogi
- 2020 Congress Sponsorship Theramex
- 2021 Consultant Theramex, Besins Speaker - Gideon Richter

Topics

- 1) Sexual function
- 2) Contraception
- 3) Childbirth
- 4) PMS
- 5) POI
- 6) Perimenopause Menopause
- 7) Prescribing HRT
- 8) Hormonal sexual dysfunction
- 9) Vulvo-vaginal atrophy
- 10) Psychosexual medicine
- 11) Summary

Human female sexual response



Physical limitations, side effects of treatments

Reduced mobility Chronic pain, arthritis Post surgical physical effects Lymphoedema Post radiotherapy – bowel / bladder Vaginal stenosis

Temporary or long lasting

Medications

SSRIs / SNRIs Anti-hormones GnRH Enzyme inducers Gabapentin



"On a positive note, video of the incident has gone on to become an internet sensation."



Anatomy


Normal anatomy

"Abnormal" anatomy episiotomy, prolapse


"Normal" surgery abdominal incision, anterior repair

Disfiguring surgery vulvectomy, circumcision

Radiotherapy scarred vagina



Desirable?



Relationship



Cause or effect?






Desire through the menstrual cycle

Some support for higher sexual interest at ovulation Some support for higher E = higher interest

And higher P = Lower interest


PMS / PMDD and lower sexual interest in luteal phase

"He comes near me at his own risk..."



Stanislaw H, Rice FJ. Correlation between sexual desire and menstrual cycle characteristics. Arch Sex Behav. 1988 Dec;17(6):499-508. doi: 10.1007/BF01542338. Kiesner J, Bittoni C, Eisenlohr-Moul T, Komisaruk B, Pastore M. Menstrual cycle-driven vs noncyclical daily changes in sexual desire. J Sex Med. 2023 May 26;20(6):756-765. doi: 10.1093/jsxmed/qdad032. Marcinkowska UM, Shirazi T, Mijas M, Roney JR. Hormonal Underpinnings of the Variation in Sexual Desire, Arousal and Activity Throughout the Menstrual Cycle - A Multifaceted Approach. J Sex Res. 2023 Nov-Dec;60(9):1297-1303. doi: 10.1080/00224499.2022.2110558. Epub 2022 Aug 26. Gollapudi M, Thomas A, Yogarajah A, Ospina D, Daher JC, Rahman A, Santistevan L, Patel RV, Abraham J, Oommen SG, Siddiqui HF. Understanding the Interplay Between Premenstrual Dysphoric Disorder (PMDD) and Female Sexual Dysfunction (FSD). Cureus. 2024 Jun 20;16(6):e62788. doi: 10.7759/cureus.62788.

Contraception



Progestogens -Progestogenic side effects

POP -

Amenorrhea

Low oestrogen

VV Atrophy

Pregnancy and postnatal

High levels E P in	<u>Postnatal</u>
pregnancy -	Lactational amenorrhea
Well-being	VV atrophy
Oestrogenic side effects	PN hormone mediated
Headache	depression
Nausea	



Premenstrual Syndrome

Symptoms that occur or increase in the luteal phase of the menstrual cycle, that completely resolve or return to baseline by the end of the period.

www.pms.org.uk



Premature ovarian insufficiency

Loss of ovarian activity <age 40 Prevalence = 1%

Diagnosis

>4/12 amenorrhea

Elevated FSH >25iu/l

on 2 occasions >4 weeks apart





Variable presentation Devastating diagnosis Can be idiopathic or iatrogenic Need psychological support Need hormonal support E P T Appropriate doses!

European Society of Human Reproduction and Endocrinology (ESHRE) Guideline on the management of Premature Ovarian Insufficiency (POI)


Panay N, Anderson RA, Bennie A, Cedars M, Davies M, Ee C, Gravholt CH, Kalantaridou S, Kallen A, Kim KQ, Misrahi M, Mousa A, Nappi RE, Rocca WA, Ruan X, Teede H, Vermeulen N, Vogt E, Vincent AJ; ESHRE, ASRM, CREWHIRL, and IMS Guideline Group on POI. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open. 2024 Dec




Premenopausal Bilateral salpingo-oophorectomy

Need BOTH E+T (and P if uterus) Remember SHBG effect Appropriate doses up to age 50 – at least

OOPHORECTOMY





Perimenopause - Short term impact

Vasomotor symptoms 60-80% women 25% women "significant" Last for 2-5 years Up to 20% flushes >10 years Huge impact on QOL **Bleeding changes** Insomnia Labile mood



Symptoms of the menopause

- Hot flushes /Night sweats Poor sleep
- Low mood / Anxiety
- Tiredness / lack of energy
- Poor concentration
- Difficulty with cognition
- Loss of self confidence
- Loss of sexual interest
- Mood swings
- Sexual dysfunction

Dryness of hair, skin, nails Urogenital atrophy **Bladder symptoms Recurrent UTIs** Vulvovaginal atrophy Superficial dyspareunia Pains in joints Pains in muscles Itchy skin Headaches

Effects of oestrogen on female body

- "Oil" that keeps the female body going
- E receptors found in most tissues
- Longer term effects
- Signs of ageing
- Collagen Skin Nails Hair Eyes Teeth
- Central thermo-regulation
- Cardiovascular system, blood vessels, atherosclerosis
- Bone thinning osteoporosis
- Brain function Alzheimers
- Bladder
- Colon cancer
- Affective disorders



Oestrogen Deficiency

> Hot flushes Night sweats

Dry eyes, tooth loss

Poor sleep

Dowager's hump

- osteoporosis

Dry hair, skin, nails

Central obesity

Memory loss poor concentration

Low mood Loss confidence Anxiety



Non-hormonal medications

Menopausal symptoms

Clonidine Gabapentin Pregabalin Citalopram Venlafaxine Zopiclone

Sexual Dysfunction Viagra Cialis (Flibanserin (5HT1 agonist)) Bupuprion


Possible Actions

Promotion of blood flow Antidepressant Anxiolytic Sedative



What is "HRT"?

- A medicine that contains sex steroid hormones –
- Either the same as the human body makes
- Or similar with similar effects




Includes:

- Oestrogens
- Progestogens
- Androgens
- (Thyroxine)

Long term Health – individualise risk

Benefits oestrogen

Symptom relief Urogenital atrophy Osteoporosis / Osteopenia Cardiovascular disease Colon cancer Alzheimers disease **Concerns oestrogen** Breast cancer VTE Stroke



International and National recommendations on HRT

International Menopause Society Statements

The IMS White Paper – Menopause and MHT in 2024: addressing the key

controversies October 2024 N. Panay et al. Climacteric

Global Consensus Position Statement on the Use of Testosterone Therapy for Women September 2019 Susan R. Davis et al. Climacteric

British Menopause Society Recommendations

BMS & WHC's 2020 recommendations on hormone replacement therapy in menopausal women March 2021 Haitham Hamoda et al

NICE guidance on Menopause

www.nice.org.uk/guidance/ng23 2015, 2024

NICE National Institute for Health and Care Excellence



Hormonal treatments – E / T / P

Oestrogens

Oral Gel Patches 

Oral tablets capsules Vaginal pessaries creams (Patches – combined)

Intrauterine systems





Androgens

Testosterone gel

Preparations - combined

Oral or patch oestradiol combined with progestogen Cyclical / continuous combined

Tibolone













Prescribing points

If uterus present need progestogen Daily or in a cycle Type of Progestogen matters

Vulvo-vaginal atrophy can be big problem Extra topical E is safe Indefinite



Continued use for well- being, no set duration or age to stop Individualised risk / benefit assessment and yearly review New use after 60 unusual – but if needed Don't start and stop – VTE Wean off slowly

Problems with HRT



Side effects

Under-dosing

Oestrogenic – breast tenderness, headaches, nausea

Progestogenic – bowel changes, headache, irritability low mood,


Androgenic – facial hair, greasy skin, hair loss

Bleeding

Dose appropriate to age Every woman is different with different metabolism and absorption Starting and stopping



Hormonal sexual dysfunction



Hormones – oestrogens and sexuality

Oestrogens have a secondary effect on arousal and libido

Relief of oestrogen deficiency symptoms
Improvement of dryness of mucus membranes (vagina/mouth/eyes)
Maintenance of secondary sexual characteristics
Improvement of skin sensitivity
Altered olfactory function and pheromone secretion
Improved higher psychological function (self-perception)



•Bachmann GA 1991

Androgens have a direct effect on sexual interest and arousal

Young women produce 350mcg T a day (3-4 x oestradiol) Half from ovaries, half from adrenals Gradual decline with age Abrupt decline with BSO Female Androgen Deficiency Syndrome

 \downarrow libido (Primary)


 \downarrow energy

 \downarrow self confidence


↑ headaches

↑ depression

Sands R, Studd J; Am J Med, 1995 Davis S, J Reprod Med, 2001



Deficiency symptoms Decreased desire, arousal, orgasm Well-being, energy, mood, self confidence Bone density, muscle mass



Prescribing Testosterone

Patient complains of reduced sexual desire

Measure total testosterone or Free androgen index = in lower third of female range (<1.0 nmol/l or <2%)

Prescribe testosterone 5mg (2-10mg) daily Be aware of local restrictions

Check levels at 3m 6m and yearly

https://thebms.org.uk/wp-content/uploads/2022/12/08-BMS-TfC-Testosterone-replacement-in-menopause-DEC2022-A.pdf NO licensed treatments for women Use 1% or 1.62% concentrations














DHEA



DHEA not available in Europe Little evidence efficacy systemically, not recommended (Vaginal Intrarosa) Food supplement in USA Weak androgenic activity




Genito-Urinary Syndrome of Menopause



Vulvo-vaginal atrophy Urinary Symptoms Sexual difficulties Sexual pain Change in vulval and clitoral sensation Decreased lubrication Difficulty in reaching orgasm

Vulvo-vaginal Atrophy

15% pre-menopausal women10-40% post-menopausal women10-25% women on HRT66% over age 75



Problems:

Recurrent UTIs

Soreness / irritation

Bleeding / trauma

Changing anatomy

Sexual difficulty

Loss of elasticity of the vagina Thinning of epithelium Reduced secretions Less acidic pH Reduced blood flow Reduced nerve transmission

> Sarrel PM Obstet Gynecol 1990;75:26s-30s Bachman et al Menopause 2004;11:120-130

Non-hormonal vaginal treatments

Moisturisers













Lubricants



Vaginal atrophy – Topical oestrogens

Intravaginal Vagifem / Vagirux / Gina Imvaggis Blissel Gel Intrarosa DHEA Cream Ovestin Ring Estring Oral Ospemifene





Use once daily for 2 weeks then twice weekly for maintenance. Indefinitely NO systemic absorption






Imvaggis










Thinking about hormones?

Listen! Individualise care HRT: consider pros/cons risks/benefits for each woman - Yearly review Know prescribing rules in your area Indefinite vaginal estrogens



Benefits almost always outweigh the risks See the specialist if problems or concerns



Segraves KB JSex Marital Ther 1991 17(1):55

Psychosexual Medicine



Institute of Psychosexual Medicine

- Brief
- Interpretative
- Psychodynamic
- Psychosexual
- Counselling

Institute of Psychosexual Medicine

> Set of skills DPR Balint groups

www.ipm.org.uk

Presentation



Institute of Psychosexual Medicine

<u>Complaints</u> Too small Too large Blockage Looks wrong Feels wrong Body fantasy

Recurrent discharge Pelvic pain Post-op problems Different symptoms Vague inconsistant symptoms

Behaviours Fear of examination Re-presenting Non-consumation Good patient Demands – sterilisation, hysterectomy Blame of HCPs

How it works



Listen

Observe

Feelings in the room - Patient or Dr?

Interpretation

Discussion

Understanding

Resolution

Why come? Why come now? When did this start? What does the patient bring?

Psychotherapeutic examination feelings revealed at time of vulnerability can be reflected

Simple questions



"How long have you had this problem?" "What do <u>you</u> think is the matter?" "How does this problem make you feel?" "How is it affecting your relationships?" "What made you tell someone about the problem now?"





Recognise and acknowledge problem together

Stay with it & consider examination to reveal what patient feels about their body

Listen –this may be the first time patient has found a nonjudgmental source of help

Share distress and acknowledge you do not have all the answers

Invite back –you may have started the healing process

Refer on – know what available / appropriate

Sexual Problems at menopause

Listen and support Holistic and personalised care Social context Discussion around feelings and implications Treatment Adequate E/T/P replacement suitable doses Vulvovaginal health, local oestrogens, moisturisers and lubricants Refer on



Patients bring us their mind and their body

Thinking about Sex?



Resources

British Menopause Society www.bms.org.uk



Women's Health Concern <u>www.womens-</u> <u>health-</u> <u>concern.org</u>

Women's Health Concern Menopause Matters www.menopausematters.co.uk



DAISY premature ovarian failure www.daisynetwork.org.uk



NAPS premenstrual syndrome <u>www.pms.org.uk</u>

Institute of Psychosexual

medicine

www.ipm.org.uk



Institute of Psychosexual Medicine



